Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions

被引：190

作者：

Hato, Tai ^{[1
]}

Goyal, Lipika ^{[2
]}

Greten, Tim F. ^{[3
]}

Duda, Dan G. ^{[1
]}

Zhu, Andrew X. ^{[2
]}

机构：

[1] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA 02114 USA

[3] NCI, Gastrointestinal Malignancy Sect, Thorac & Gastrointestinal Oncol Branch, Bethesda, MD 20892 USA

来源：

HEPATOLOGY | 2014年 / 60卷 / 05期

基金：

美国国家卫生研究院;

关键词：

REGULATORY T-CELLS; PERCUTANEOUS ETHANOL INJECTION; SUPPRESSOR-CELLS; POSTOPERATIVE RECURRENCE; CTLA-4; BLOCKADE; LIVER; RESPONSES; PD-1; MOLECULES; HEPATITIS;

D O I：

10.1002/hep.27246

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.

引用

页码：1776 / 1782

页数：7

共 50 条

[41] Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
Abboud, Karen
Umoru, Godsfavour
Esmail, Abdullah
Abudayyeh, Ala
Murakami, Naoka
Al-Shamsi, Humaid O. O.
Javle, Milind
Saharia, Ashish
Connor, Ashton A. A.
Kodali, Sudha
Ghobrial, Rafik M. M.
Abdelrahim, Maen
CANCERS, 2023, 15 (05)
[42] The future of microfluidics in immune checkpoint blockade
Briones, Jonathan
Espulgar, Wilfred
Koyama, Shohei
Takamatsu, Hyota
Tamiya, Eiichi
Saito, Masato
CANCER GENE THERAPY, 2021, 28 (09) : 895 - 910
[43] The future of microfluidics in immune checkpoint blockade
Jonathan Briones
Wilfred Espulgar
Shohei Koyama
Hyota Takamatsu
Eiichi Tamiya
Masato Saito
Cancer Gene Therapy, 2021, 28 : 895 - 910
[44] Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
Si-Qi Li
Yang Yang
Lin-Sen Ye
World Journal of Gastroenterology, 2022, 28 (42) : 6034 - 6044
[45] Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
Li, Si-Qi
Yang, Yang
Ye, Lin-Sen
WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (42) : 6034 - 6044
[46] Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
Fan Zhongqi
Sun Xiaodong
Chen Yuguo
Lv Guoyue
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (02) : 222 - 228
[47] IDENTIFICATION OF A HOST FACTOR FOR THE IMPROVEMENT OF IMMUNE CHECKPOINT BLOCKADE THERAPY FOR HEPATOCELLULAR CARCINOMA
Murai, Kazuhisa
Honda, Masao
Shirasaki, Takayoshi
Kaneko, Shuichi
HEPATOLOGY, 2019, 70 : 808A - 809A
[48] Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni, Riccardo
Rizzo, Alessandro
Ricci, Angela Dalia
Frega, Giorgio
Di Federico, Alessandro
Palloni, Andrea
Di Marco, Mariacristina
Gadaleta-Caldarola, Gennaro
Brandi, Giovanni
FUTURE ONCOLOGY, 2022, 18 (08) : 1023 - 1034
[49] Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions
Riccardo Inchingolo
Alessandro Posa
Martin Mariappan
Stavros Spiliopoulos
World Journal of Gastroenterology, 2019, 25 (32) : 4614 - 4628
[50] Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
Yavuz, Betul Gok
Hasanov, Elshad
Lee, Sunyoung S.
Mohamed, Yehia, I
Curran, Michael A.
Koay, Eugene J.
Cristini, Vittorio
Kaseb, Ahmed O.
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 1195 - 1207

← 1 2 3 4 5 →